GET THE APP

..

Journal of Inflammatory Bowel Diseases & Disorders

ISSN: 2476-1958

Open Access

Role/Risks of Proton Pump Inhibitors and Infliximab in IBD Patients

Abstract

Lim Vuanghao*

Proton Pump Inhibitors (PPIs) are the most generally endorsed class of medicine for the treatment of indigestion and corrosive related issues. They work by obstructing the site of corrosive creation in the parietal cell of the stomach. Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases mainly Ulcerative Colitis (UC) and Crohn's Disease (CD). Infliximab targets TNF, thought to be more related to Th1 cytokines.

HTML PDF

Share this article

Google Scholar citation report
Citations: 77

Journal of Inflammatory Bowel Diseases & Disorders received 77 citations as per Google Scholar report

Journal of Inflammatory Bowel Diseases & Disorders peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward